Experts warned that the National Institute for Health and Care Excellence (NICE) is disappointing breast cancer patients by rejecting new drugs.
According to Daily Mail, NICE has not approved a single treatment for the disease in 10 years.
The Breast Cancer Now charity said NICE’ method for evaluating new drugs places primary focus on comparing the cost of a breakthrough new treatment with the price of existing breast cancer drugs and is seriously flawed.
The charity said none of the drugs that have come to the market since 2007 have been approved including drugs that were given the green light by Canada, Australia, Germany and France.
Kadcyla and Perjeta reportedly meant to treat HER2-positive breast cancer type with trials of both drugs showing life extension and likelihood of tumours being eradicated.
The charity lamented that NICE is failing to recognise that new drugs have the potential to extend women’s lives by a few years compared to current medicines.
Breast Cancer Now is concerned that NICE has also taken control of the Cancer Drugs Fund, used to pay for treatments not available on the NHS.
Chief executive of NICE, Sir Andrew Dillon said the system evaluated cancer drugs far more ‘generously’ than those for other conditions.
Dillon added that it welcomes the charity’s contribution to the debate, however changing NICE’s evaluation system is not the solution.
“Any change in our approach has to be accompanied by a sustained and material change in the cost of these drugs to the NHS,” he concluded.